Journal of Experimental MedicineImmunologyPeer-reviewed journal article
Maternally transferred monoclonal antibodies protect neonatal mice from herpes simplex virus-induced mortality and morbidity
I. M. Backes, B. K. Byrd, C. D. Patel, S. A. Taylor, C. R. Garland, S. W. MacDonald, A. B. Balazs, S. C. Davis, M. E. Ackerman, D. A. Leib
Abstract
Neonatal herpes simplex virus (HSV) infections often result in significant mortality and neurological morbidity despite antiviral drug therapy. Maternally-transferred HSV-specific antibodies reduce the risk of clinically-overt neonatal HSV (nHSV), but this observation has not been translationally applied. Using a neonatal mouse model, we tested the hypothesis that passive transfer of HSV-specific human monoclonal antibodies (mAbs) can prevent mortality and morbidity associated with nHSV. The mAbs were expressed in vivo by vectored immunoprophylaxis, or administered in vivo following recombinant expression in vitro. Through these maternally-derived routes or through direct administration to pups, diverse mAbs to HSV glycoprotein D protected against neonatal HSV-1 and HSV-2 infection. Using in vivo bioluminescent imaging, both pre- and post-exposure mAb treatment significantly reduced viral load. Administration of mAb also reduced nHSV-induced behavioral morbidity, as measured by anxiety-like behavior. Together these studies support the notion that HSV-specific mAb-based therapies may prevent or improve HSV infection outcomes in neonates. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=93 SRC="FIGDIR/small/476098v1_ufig1.gif" ALT="Figure 1"> View larger version (29K): org.highwire.dtl.DTLVardef@175f6eaorg.highwire.dtl.DTLVardef@1a59e39org.highwire.dtl.DTLVardef@36c484org.highwire.dtl.DTLVardef@19fec96_HPS_FORMAT_FIGEXP M_FIG C_FIG Different antibody sources were used to maternally-transfer or directly administer HSV-specific mAbs to mouse pups. Neonatal mice were challenged with wild type or bioluminescent virus before or after mAb acquisition. Following infection, pups were assessed for survival, virus-induced bioluminescence and anxiety-like behavior as a measure of neurological morbidity. Efficacy was time and mAb dependent. Notably, all HSV-specific mAbs prevented nHSV-associated mortality.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Antibody effector functions are required for broad and potent protection of neonates from herpes simplex virus infection
M. D. Slein, I. M. Backes, … M. E. Ackerman·bioRxiv·Aug 29, 2023
- Antibodies targeting HSV glycoprotein B require effector functions to protect neonatal mice
Matthew D. Slein, Lesle M Jimenez, … Margaret E. Ackerman·Journal of VirologyPeer-reviewed·Mar 9, 2026
- Asymptomatic neonatal herpes simplex virus infection in mice leads to long-term cognitive impairment
Abigail J. Dutton, C. D. Patel, … David A. Leib·PLoS PathogensPeer-reviewed·Feb 7, 2025
- Prefusion-specific glycoprotein B human antibodies protect against neonatal HSV-2 infection
Parastoo Amlashi, 김정렬, … Ivelin S. Georgiev·bioRxiv·Mar 26, 2026
- Preexisting antibodies can protect against congenital cytomegalovirus infection in monkeys
C. S. Nelson, D. V. Cruz, … S. R. Permar·bioRxiv·Apr 15, 2017
- Interaction with complement factor C1q can contribute to and improve monoclonal antibody-mediated protection against lethal HSV-1 challenge
Lesle M Jimenez, Matthew D. Slein, … Margaret E. Ackerman·bioRxiv·Oct 24, 2026